Galectin Therapeutics Inc 2026年季度报告

FORM 10-Q ☒Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2026 Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 001-31791 GALECTIN THERAPEUTICS INC. Nevada04-3562325(State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.) 4960 Peachtree Industrial Blvd., Suite 240, Norcross, GA30071(Address of Principal Executive Offices)(Zip Code) (678) 620 -3186(Registrant’s Telephone Number, Including Area Code) Securities registered or to be registered pursuant to Section 12(b) of the Act. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.☒Yes☐No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).☒Yes☐No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large Accelerated Filer☐Non-Accelerated Filer☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☒No The number of shares outstanding of the registrant’s common stock as of May 8, 2026 was 65,856,898. GALECTIN THERAPEUTICS INC.INDEX TO FORM 10-QFOR THE QUARTER ENDED MARCH 31, 2026 Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20252Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026 and 20253Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20254Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’Deficit for the three months ended March 31, 2026 and 20255Notes to Unaudited Condensed Consolidated Financial Statements6ITEM 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations19ITEM 3.Quantitative and Qualitative Disclosures about Market Risk27ITEM 4.Controls and Procedures28PART II — OTHER INFORMATIONITEM 1.Legal Proceedings28ITEM 1A.Risk Factors28ITEM 2.Unregistered Sales of Equity Securities and Use of Proceeds28ITEM 3.Defaults Upon Senior Securities28ITEM 4.Mine Safety Disclosures28ITEM 5.Other Information28ITEM 6.Exhibits28SIGNATURES30 Index ASSETS Index Index Index Index GALECTIN THERAPEUTICS INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. Basis of Presentation and Liquidity Galectin Therapeutics Inc. and subsidiaries (the “Company”) is a clinical stage biopharmaceutical company that is applyingits leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates arebased on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compoundsalso may have application for drugs to treat other diseases and chronic health conditions. The unaudited condensed consolidated financial statements as reported in this Quarterly Report on Form 10-Q reflect alladjustments which are, in the opinion of management, necessary to present fairly the financial position of the Company as of March31, 2026 and the results of its operations for the three months ended March 31, 2026 and 2025 and its cash flows for the three monthsended March 31, 2026 and 2025. All adjustments made to the interim financial statements include all those of a normal and recurringnature. Amounts presented in the condensed consolidated balance sheet as of December 31, 2025 are derived from the Company’saudited consolidated financial statements as of that date, but do not include all of the information and footnotes required by accountingprinciples generally accepted in the United States of America for complete financial statements. The Company considers events ortransactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relativeto certain estimates or to identify